Member Info for MrRipley

The chances of them announcing a science day with near no notice seem vanishingly small.

It’s going in the mental ahhh fudge this draw now til Christmas. The waits now boring. Good news though Bein…. No science day, but Elon Musk has decided to lift all Twitter bans, so I can take out all my boredom on TW.

No thats Lidl you’re thinking of. ALDIs is Colin the Cancer-Pil-Ar.

On the TV there. The ice cream market is worth the same (give or take) per annum…. As dox. So hence forth, and without delay, Sir Al, aka Waffle Al, King of Abakta, shall be known as the ice cream man. I’ll take a 99….. pounds per share. What what.

“Believe me or don’t”

……………………………………. I don’t. I get it for just 5k in the middle isle in Aldi. Pour it on my roses. They’ve started growing apples. No need to thank me.

Here you go Runner. Give these a call in the morning. Tell them that they need to speak to this “Doctor” because they’ve got it horrifically wrong. This is the reference Avacta use for the potential size of the market if Dox alone. Crazy this isn’t it. Me. A builder. I’ve managed to actually read what the RNS says AND look at the reference. Here’s a tip…. I believe that by the year 2024, bricks will no longer be used and it’s more likely that people will all live in bouncy castles with a papier-mâché roof on top because it’s much cheaper and faster to build than a traditional building. Plus if it gets subsidence it only needs a quick pump and it’s back to normal. Therefore along with the brick market, I also think the bed market is foxed because you can just sleep on the floor. It’s really squishy. Remember, take my advice, I’m a builder. Anyone else who suggests otherwise is just stupid.

https://www.prnewswire.com/news-releases/doxorubicin-market-size-is-expected-to-reach-138-billion-by-2024-grand-view-research-inc-602613665.html

Think about how stupid that remark is. You believe that Avacta, who have spent a vast amount of time, along with a team of experts in their fields, along with analysts considering the market size and references to those market sizes within their RNSs have somehow got this entirely wrong and a dr who has more than likely spent no time at all considering the above as he’s too busy working as a Dr, somehow has it right? This imaginary Dr, knows more about the product and the market than the team of Drs in the multi million £ company spending vast sums analysing the opportunity? It’s not about my profession here it, it’s about my capacity for abstract thought and critical analysis, which is something you clearly do not possess, proven by your unprepossessing opinion of my means of earning a living. You silly twat.

Firstly I very much doubt any info would be handed out to anyone outside of the trial.

Secondly;

“It may ultimately supplant standard doxorubicin for those patients expected to have incomplete resection or repeated course for some other reason.”

Is the dumbest thing I’ve read in a while. Why, on earth, would they opt for a higher rate and more severe side effects for a drug that will ultimately lead to greater costs to the NHS for care beyond chemo, due to damage from they drug, if they even survive. Also it’ll probably be a case that it takes a lot less care overall if the chemo is more targeted and effective. Therefore your “friend” is talking total rubbish on the cost front.

Then your friend wrote this, and outdone themselves;

“Thus the target population is much smaller than you might think.”

We don’t think though do we. We literally know the size of the dox market. It’s circa $1.5bn per annum with current restrictions on use. It’s also not just about dox; it’s about the entire platform.

Also, you might want to give the likes of Roche a shout, let them know to stop trying to find a FAB activated therapeutic, because you’re friend said it’s not worth the effort.

It is remarkable if a tiny Yorkshire biotech run by lowly northerners has outdone the likes of Roche. Have they done it? How well have they done it? And what’s it worth. If you’re a casual investor in the Twitter # favourites then you won’t do the research. This one is for the bigger fish. Us minnows are tagging along. If it works we’ll be up there with the early Microsoft investors in the legends of investing. And I can get bouncing hydraulics fitted onto my golden transit van.

I can’t use a 2 step ladder without an H+S sign off. They aren’t injecting terminally Ill patients for a year and a half with saline. It’s just a matter of how well it’s working now.

RAH….. we all really appreciate the incredible amount of research and opinion you bring; but when you find a gold mine, sometimes it’s best to fill your pockets quietly while you can.

Unpopular opinion….. Andy doesn’t know when RNS’ are coming. There. I said it. And Ophidians special Sauce is actually mint…. That’s why he’s on the lamb from this board.

Drops mic. Exits left stage. Peeps round the curtain.

It means nothing and won’t help at all with what you’re going through, but my absolute deepest sympathies to you and all close to him. And I totally agree, humanity needs us, or anyone, to find a better way. Life can be incredibly cruel, but in that cruelty you can find the best in people around you; so stick together and take care of one another.

No they actually have it constantly on now. And it’s eco friendly too; they just get meth addicts into a big hamster wheel and they just sprint! It keeps it at 200% power at all times.

In other news…. Much better board today.

Jive, I reckon anyone waiting for results, even on the other side of the pond, will still check for news.

100% probably maybe nailed on for certain.

Using this as the link as the follow up comment is good too. Tap the tagged post. Nice, if relatively basic, summary.

https://mobile.twitter.com/250kchip/status/1595370172537360385

Complete and utter *******s.

PAH and Bein both make very solid points here Robbo. As do you with us being 3 weeks over the timeframe of the last Cohort. I believe this week, it’s possible we’ll have news. As Bein has pointed out, Avacta have told us the time frame to expect. You’d assume they’re pretty clued up on their own trial. I also think it’s safe to say that since we’re so far beyond the time expected for this cohort to end that there won’t be another. So next RNS will either be Data, or TMAC news, which as pointed out by many here, inc myself, would be as good as confirmation that it works since you wouldn’t want to be wasting money on 2 platforms that don’t work when they are intrinsically linked.

Anyway…. I’m off for a day in the rain. Very hard to type twat at people when you’re thumbs are frozen.

Toodle pip.

….. have you broken into the Christmas supply of Baileys a little early? Creamy. Beige.